论文部分内容阅读
为观察急性心肌梗死（ＡＭＩ）患者血小板活化状态的改变及临床意义，采用血小板表面抗人活化型α颗粒膜蛋白－１４０（ＧＭＰ－１４０）及血小板膜糖蛋白Ⅱｂ·Ⅲａ复合物（ＧＰⅡｂ·Ⅲａ）的单克隆抗体，以酶联免疫法检测１９例ＡＭＩ患者血小板活化状态，将其与２５例正常对照者对比，并分别与心肌酶及血栓素（ＴＸＢ_２）作相关分析。结果ＡＭＩ组血小板ＧＭＰ－１４０、ＧＰⅡｂ·Ⅲａ分子数明显高于正常对照组（均Ｐ＜０．０１）。同时显示ＧＭＰ－１４０和ＧＰⅡｂ·Ⅲａ增高均与血清肌酸激酶、肌酸激酶同功酶、乳酸脱氢酶、ＴＸＢ_２呈正相关（均Ｐ＜０．０１）。表明血小板活化功能检测对ＡＭＩ的诊治有一定临床价值。
In order to observe the changes and clinical significance of platelet activation in patients with acute myocardial infarction (AMI), the effects of platelet surface anti-human activated α-granule membrane protein-140 (GMP-140) and platelet glycoprotein Ⅱb · Ⅲa complex ) Monoclonal antibody was detected by enzyme-linked immunosorbent assay in 19 patients with acute myocardial infarction (AMI). The platelet activation status of 19 AMI patients was compared with that of 25 healthy controls. The levels of TXB2 and TXB2 were detected respectively. Results The number of platelet GMP-140 and GPⅡb · Ⅲa in AMI group was significantly higher than that in normal control group (all P <0.01). Simultaneously, the increase of GMP-140 and GPⅡb · Ⅲa were positively correlated with creatine kinase, creatine kinase, lactate dehydrogenase and TXB 2 (all P <0.01). That platelet activation test for the diagnosis and treatment of AMI have some clinical value.